HIV-1 entry into cells is an attractive target for new antiviral agents. But will inhibitors aimed at the CCR5 co-receptor force HIV-1 to evolve more virulent forms? Other targets for entry ...

C-28 modified betulinic acid analogs are potent HIV entry inhibitors, while C-3 modified betulinic acid derivatives function by blocking virus maturation. [127] Among these bevirimat (Figure 23 ...

offers a new and fourth class of antiretroviral agents called fusion (or entry) inhibitors. Enfuvirtide was approved for use in treatment-experienced patients who still have evidence of viral ...

protease inhibitors; entry inhibitors; integrase (strand transfer) inhibitors. Entry inhibitors stop HIV from entering human cells. These include fusion inhibitors, CCR5 inhibitors and attachment ...

entry inhibitor candidate. This Phase 1a study will evaluate the safety, tolerability and pharmacokinetics (PK) of ABI-6250 across single and multiple ascending dose cohorts in healthy participants.

NNRTI-based HAART regimens have quickly become the preferred choice for initial anti-retroviral therapy, whereas drugs from the newest classes, such as Roche and Pfizer's entry inhibitors and ...